Study design and population
deafness, cerebral hemorrhage, Stroke, blindness, organic mental disorder, infection, post-infarction hemorrhage, hepatic and renal insufficiency, hyperkalemia, hypotension, communication disorders, hypertension, schizophrenia, affective disorder, trauma
CEREBRAL HEMORRHAGE, AORTIC DISSECTION, STROKE, TRANSIENT ISCHEMIC ATTACK, BLINDNESS, CARDIAC INSUFFICIENCY, MAY, INFECTION, SEPTIC SHOCK, HYPERTENSIVE ENCEPHALOPATHY, HYPERTENSION, NEOPLASTIC DISEASE
Our study was a randomized, controlled, parallel-group trial conducted at the Stroke Center of Lianyungang Second People’s Hospital. From 1st May 2021 to 31st June 2022, 80 patients aged ≥18 years who had ACI confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) of the brain within 48 hours of symptom onset and required antihypertensive therapy (Real-time systolic BP ≥180mmHg or diastolic BP≥100mmHg, or patients with severe cardiac insufficiency, aortic dissection, hypertensive encephalopathy, or having a history of hypertension and regularly taking anti-hypertensive medication) were consecutively enrolled. Patients who fulfilled one of the following conditions were excluded from the trial: (1) Patients with cerebral hemorrhage and occupancy (emergency head CT excludes cerebral hemorrhage, while post-infarction hemorrhage is not excluded if the patient was hospitalized); (2) Patients with transient ischemic attack; (3) Complicated with severe infection or septic shock; (4) Combined with hypotension or hyperkalemia; (5) Obvious hepatic and renal insufficiency (glomerular filtration rate <30ml/min or Child-Pugh class C); (6) Endocrine, immune, or neoplastic diseases; (7) History of severe trauma with surgical treatment within 30 days; (8) Presence of blindness, deafness or communication disorders; (9) Diagnosed as schizophrenia, affective disorder, organic mental disorder or mental retardation; (10) had a contraindication to sacubitril/valsartan; (11) Pregnancy. All patients provided written informed consent. This trial received ethical approval from the ethics committees of Lianyungang Second People’s Hospital (No.2020010), and it was registered in the Chinese Clinical Trials Registry (ChiCTR2100047408).